‘CRUSH USH’ The Central Committee on Research Involving Human Subjects (CCMO) has given the Usher Syndrome expertise centre in Radboud UMC permission to actually start the CRUSH study. The CCMO assesses whether medical scientific research complies with the legal stipulations. With this the CCMO guarantees the protection of participants of
The RUSH2a and the CRUSH studies By now, both the RUSH2a and the CRUSH studies have been started in the Usher Syndrome Expertise Centre in Radboud UMC in Nijmegen, the Netherlands. What are the differences and the similarities? We will explain below. CRUSH has been aligned to RUSH2aAlso thanks to
Stichting Ushersyndroom finances CRUSH study The expertise centre for Usher Syndrome in Radboudumc in Nijmegen (the Netherlands) will start a natural development study into Usher Syndrome. This is a very important step in the research into a treatment of Usher Syndrome, because this study may substantially shorten the running time
Stichting Ushersyndroom will finance the start of the CRUSH study, a natural development study into Usher Syndrome. With this the basis can be laid for future trials. Patients can, with their own files at hand, register for the CRUSH database and so bear the responsibility for the solution and the
Last week we received the great news about the upcoming first trials in the study into Usher Syndrome. Foundation Fighting Blindness will invest $7,5 million in the pharmaceutical company ProQR for setting up the first clinical trial for patients with retina degeneration caused by mutations in USH2A exon 13. This
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A Foundation Fighting Blindness and ProQR Therapeutics N.V. , announced that they have entered into a partnership to develop QR-421a for Usher syndrome 2A caused by an exon 13 mutation
Source: Usher syndrome Coalition USH Talk By Hannie Kremer Date: 30 – 5 – 2017 In this USH Talk, Dr. Hannie Kremer explains genetic testing of the USH2A gene, as conducted at the Radboud University Medical Center in Nijmegen, Netherlands. The type of DNA defects found in this gene is
Source: Radboudumc 22 March 2017 The American Foundation Fighting Blindness has granted two important subsidies to researchers of the Radboudumc for a total amount of five million dollars. With this the researchers can further develop therapies for hereditary diseases of the retina and Usher Syndrome for the next five years.